67th Annual Scientific Meeting of the American Headache Society 2025

CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »

Latest:

Can CGRP mAbs make IHS treatment goals a reality?Access issues make CGRP mAb treatment a challenge in Ukraine GLP-1 agonist reduces headache days by indirect effect on CGRP CGRP mAbs effective in chronic migraine refractory to BoNT-A CGRP mAbs more effective outside perimenstrual period Rimegepant produces consistent responses to migraine attacks Atogepant superior to topiramate in Phase 3 TEMPLE study Ubrogepant may relieve common prodromal symptoms

It seems we can’t find what you’re looking for. Perhaps searching can help.

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

404 Nothing Found

Trials

Latest News

Resources